Evidence-based treatment of early-stage melanoma

Journal of Surgical Oncology

Volumn 104, Issue 4, 2011, Pages 341-353

  Ross, Merrick I ^a   Gershenwald, Jeffrey E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

guideline compliance; lymph node dissection; melanoma; sentinel lymph node biopsy; staging; wide excision

Indexed keywords

CANCER CONTROL; CANCER INVASION; CANCER PATIENT; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; DISEASE COURSE; DISEASE FREE SURVIVAL; EARLY CANCER; ELECTIVE SURGERY; EVIDENCE BASED PRACTICE; HISTOPATHOLOGY; HUMAN; IN-TRANSIT METASTASIS; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MELANOMA; MICROMETASTASIS; OVERALL SURVIVAL; POSTOPERATIVE COMPLICATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; TUMOR VOLUME;

CLINICAL TRIALS AS TOPIC; EVIDENCE-BASED MEDICINE; GUIDELINE ADHERENCE; HUMANS; LYMPH NODE EXCISION; MELANOMA; NEOPLASM STAGING; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS;

EID: 80051987668     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.21962     Document Type: Review

References (92)

1. Edge SE, Byrd DR, Compton CC, et al.: editors. AJCC Cancer Staging Manual. New York, NY: Springer; 2009.
2. Balch CM, Gershenwald JE, Soong SJ, et al.: Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009; 27: 6199-6206.
3. Pringle J:, A method of operation in melanotic tumours of the skin. Edinburgh Med J 1908; 23: 496.
4. Bono A, Bartoli C, Clemente C, et al.: Ambulatory narrow excision for thin melanoma (< or =2 mm): Results of a prospective study. Eur J Cancer 1997; 33: 1330-1332. (Pubitemid 27359656)
5. Handley WS:, The Bunterian lectures on the pathology of melanotic growths in relation to their operative treatment. Lancet 1907; 169: 927-933.
6. Wong CK:, A study of melanocytes in the normal skin surrounding malignant melanomata. Dermatologica 1970; 141: 215-225.
7. Olsen G:, The malignant melanoma of the skin: New theories based on a study of 500 cases. Acta Chir Scand Suppl 1966; 365: 1-222.
8. Breslow A, Macht SD:, Optimal size of resection margin for thin cutaneous melanoma. Surg Gynecol Obstet 1977; 145: 691-692. (Pubitemid 8225365)
9. Balch CM, Murad TM, Soong SJ, et al.: Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 1979; 43: 883-888. (Pubitemid 9163616)
10. Cosimi AB, Sober AJ, Mihm MC, Fitzpatrick TB:, Conservative surgical management of superficially invasive cutaneous melanoma. Cancer 1984; 53: 1256-1259. (Pubitemid 14198881)
11. Day CL Jr, Mihm MC Jr, Sober AJ, et al.: Narrower margins for clinical stage I malignant melanoma. N Engl J Med 1982; 306: 479-482. (Pubitemid 12171680)
12. Elder DE, Guerry Dt, Heiberger RM, et al.: Optimal resection margin for cutaneous malignant melanoma. Plast Reconstr Surg 1983; 71: 66-72. (Pubitemid 13179431)
13. Goldman LI, Byrd R:, Narrowing resection margins for patients with low-risk melanoma. Am J Surg 1988; 155: 242-244. (Pubitemid 18070637)
14. Kelly JW, Sagebiel RW, Calderon W, et al.: The frequency of local recurrence and microsatellites as a guide to reexcision margins for cutaneous malignant melanoma. Ann Surg 1984; 200: 759-763. (Pubitemid 15216759)
15. O'Rourke MG, Altmann CR:, Melanoma recurrence after excision: Is a wide margin justified ? Ann Surg 1993; 217: 2-5. (Pubitemid 23033211)
16. W.H.O. Collaborating centres for evaluation of methods of diagnosis and treatment of melanoma. Stage I melanoma of the skin: The problem of resection margins. Eur J Cancer 1980; 16: 1079-1085.
17. Milton GW, Shaw HM, McCarthy WH:, Resection margins for melanoma. Aust N Z J Surg 1985; 55: 225-226. (Pubitemid 15021725)
18. Khayat D, Rixe O, Martin G, et al.: Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick). Cancer 2003; 97: 1941-1946.
19. Veronesi U, Cascinelli N, Adamus J, et al.: Thin stage I primary cutaneous malignant melanoma: Comparison of excision with margins of 1 or 3 cm. N Engl J Med 1988; 318: 1159-1162.
20. Veronesi U, Cascinelli N:, Narrow excision (1-cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991; 126: 438-441.
21. Cascinelli N:, Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998; 14: 272-275. (Pubitemid 28211035)
22. Cohn-Cedermark G, Rutqvist LE, Andersson R, et al.: Long term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8-2.0 mm. Cancer 2000; 89: 1495-1501.
23. Ringborg U, Andersson R, Eldh J, et al.: Resection margins of 2 versus 5 cm for cutaneous malignant melanoma with a tumor thickness of 0.8 to 2.0 mm: Randomized study by the Swedish Melanoma Study Group. Cancer 1996; 77: 1809-1814. (Pubitemid 26125180)
24. Marsden JR:, Malignant melanoma excision margins: Melanoma Study Group. Lancet 1993; 341: 184. (Pubitemid 23029346)
25. Balch CM, Urist MM, Karakousis CP, et al.: Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm): Results of a multi-institutional randomized surgical trial. Ann Surg 1993; 218: 262-267, Discussion 267-269.
26. Karakousis CP, Balch CM, Urist MM, et al.: Local recurrence in malignant melanoma: Long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 1996; 3: 446-452. (Pubitemid 126728589)
27. Balch CM, Soong S, Ross MI, et al.: Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm): Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000; 7: 87-97. (Pubitemid 30164676)
28. Balch CM, Soong SJ, Smith T, et al.: Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 2001; 8: 101-108. (Pubitemid 32199405)
29. Thomas JM, Newton-Bishop J, A'Hern R, et al.: Excision margins in high-risk malignant melanoma. N Engl J Med 2004; 350: 757-766. (Pubitemid 38209645)
30. Ringborg U:, Swedish Melanoma Study Group prelim report. 6th World Congress on melanoma. Vancouver: Canada; 2005.
31. Schneebaum S, Briele HA, Walker MJ, et al.: Cutaneous thick melanoma: Prognosis and treatment. Arch Surg 1987; 122: 707-711. (Pubitemid 17084578)
32. Spellman JE Jr, Driscoll D, Velez A, Karakousis C:, Thick cutaneous melanoma of the trunk and extremities: An institutional review. Surg Oncol 1994; 3: 335-343.
33. Ball AS, Thomas J:, Surgical management of malignant melanoma. Br Med Bull 1995; 51: 584-608.
34. Heaton KM, Sussman JJ, Gershenwald JE, et al.: Surgical margins and prognostic factors in patients with thick (>4 mm) primary melanoma. Ann Surg Oncol 1998; 5: 322-328. (Pubitemid 28272435)
35. NIH Consensus Conference. Diagnosis and treatment of early melanoma. JAMA 1992; 268: 1314-1319.
36. McKinnon JG, Starritt EC, Scolyer RA, et al.: Histopathologic excision margin affects local recurrence rate: Analysis of 2681 patients with melanomas < or =2 mm thick. Ann Surg 2005; 241: 326-333.
37. Haigh PI, DiFronzo LA, McCready DR:, Optimal excision margins for primary cutaneous melanoma: A systematic review and meta-analysis. Can J Surg 2003; 46: 419-426. (Pubitemid 38315579)
38. Lens MB, Nathan P, Bataille V:, Excision margins for primary cutaneous melanoma: Updated pooled analysis of randomized controlled trials. Arch Surg 2007; 142: 885-891, Discussion 891-883. (Pubitemid 47437312)
39. Johnson TM, Sondak VK:, Melanoma margins: The importance and need for more evidence-based trials. Arch Dermatol 2004; 140: 1148-1150. (Pubitemid 39223124)
40. Sim FH, Taylor WF, Pritchard DJ, Soule EH:, Lymphadenectomy in the management of stage I malignant melanoma: A prospective randomized study. Mayo Clin Proc 1986; 61: 697-705. (Pubitemid 16011485)
41. Ross MI:, Surgical management of stage I and II melanoma patients: Approach to the regional lymph node basin. Semin Surg Oncol 1996; 12: 394-401. (Pubitemid 26371321)
42. Balch CM, Gershenwald JE, Soong SJ, et al.: Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: Comparison of nodal micrometastases versus macrometastases. J Clin Oncol 2010; 28: 2452-2459.
43. Balch CM, Soong SJ, Gershenwald JE, et al.: Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 2001; 19: 3622-3634. (Pubitemid 32786275)
44. Ballo MT, Strom EA, Zagars GK, et al.: Adjuvant irradiation for axillary metastases from malignant melanoma. Int J Radiat Oncol Biol Phys 2002; 52: 964-972. (Pubitemid 34219015)
45. Calabro A, Singletary SE, Balch CM:, Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 1989; 124: 1051-1055. (Pubitemid 19231243)
46. Gershenwald JE, Berman RS, Porter G, et al.: Regional nodal basin control is not compromised by previous sentinel lymph node biopsy in patients with melanoma. Ann Surg Oncol 2000; 7: 226-231. (Pubitemid 30215162)
47. Lee RJ, Gibbs JF, Proulx GM, et al.: Nodal basin recurrence following lymph node dissection for melanoma: Implications for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys 2000; 46: 467-474. (Pubitemid 30067798)
48. O'Brien CJ, Coates AS, Petersen-Schaefer K, et al.: Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 1991; 162: 310-314.
49. Slingluff CL Jr, Stidham KR, Ricci WM, et al.: Surgical management of regional lymph nodes in patients with melanoma: Experience with 4682 patients. Ann Surg 1994; 219: 120-130. (Pubitemid 24064068)
50. Cascinelli N, Morabito A, Santinami M, et al.: Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial. WHO Melanoma Programme. Lancet 1998; 351: 793-796. (Pubitemid 28112341)
51. Veronesi U, Adamus J, Bandiera DC, et al.: Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977; 297: 627-630. (Pubitemid 8200048)
52. Morton DL, Wen DR, Wong JH, et al.: Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992; 127: 392-399.
53. Reintgen D, Cruse CW, Wells K, et al.: The orderly progression of melanoma nodal metastases. Ann Surg 1994; 220: 759-767. (Pubitemid 24376374)
54. Ross MI, Reintgen D, Balch CM:, Selective lymphadenectomy: Emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993; 9: 219-223. (Pubitemid 23154458)
55. Thompson JF, McCarthy WH, Bosch CM, et al.: Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995; 5: 255-260.
56. Gershenwald JE, Tseng CH, Thompson W, et al.: Improved sentinel lymph node localization in patients with primary melanoma with the use of radiolabeled colloid. Surgery 1998; 124: 203-210. (Pubitemid 28372917)
57. Gershenwald JE, Colome MI, Lee JE, et al.: Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 1998; 16: 2253-2260. (Pubitemid 28265065)
58. Cascinelli N, Belli F, Santinami M, et al.: Sentinel lymph node biopsy in cutaneous melanoma: The WHO Melanoma Program experience. Ann Surg Oncol 2000; 7: 469-474. (Pubitemid 30439307)
59. Thompson JF:, The Sydney Melanoma Unit experience of sentinel lymphadenectomy for melanoma. Ann Surg Oncol 2001; 8: 44S-47S.
60. Doeden K, Ma Z, Narasimhan B, et al.: Lymphatic invasion in cutaneous melanoma is associated with sentinel lymph node metastasis. J Cutan Pathol 2009; 36: 772-780.
61. McMasters KM, Wong SL, Edwards MJ, et al.: Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma. Surgery 2001; 130: 151-156. (Pubitemid 32721662)
62. Paek SC, Griffith KA, Johnson TM, et al.: The impact of factors beyond Breslow depth on predicting sentinel lymph node positivity in melanoma. Cancer 2007; 109: 100-108. (Pubitemid 46120199)
63. Petersson F, Diwan AH, Ivan D, et al.: Immunohistochemical detection of lymphovascular invasion with D2-40 in melanoma correlates with sentinel lymph node status, metastasis and survival. J Cutan Pathol 2009; 36: 1157-1163.
64. Rousseau DL Jr, Ross MI, Johnson MM, et al.: Revised American Joint Committee on Cancer staging criteria accurately predict sentinel lymph node positivity in clinically node-negative melanoma patients. Ann Surg Oncol 2003; 10: 569-574. (Pubitemid 40486922)
65. Sondak VK, Taylor JM, Sabel MS, et al.: Mitotic rate and younger age are predictors of sentinel lymph node positivity: Lessons learned from the generation of a probabilistic model. Ann Surg Oncol 2004; 11: 247-258. (Pubitemid 40486764)
66. Thompson JF, Shaw HM:, Should tumor mitotic rate and patient age, as well as tumor thickness, be used to select melanoma patients for sentinel node biopsy ? Ann Surg Oncol 2004; 11: 233-235. (Pubitemid 40486758)
67. Gershenwald JE, Thompson W, Mansfield PF, et al.: Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 1999; 17: 976-983. (Pubitemid 29109331)
68. Cascinelli N, Bombardieri E, Bufalino R, et al.: Sentinel and nonsentinel node status in stage IB and II melanoma patients: Two-step prognostic indicators of survival. J Clin Oncol 2006; 24: 4464-4471. (Pubitemid 46630985)
69. Clary BM, Brady MS, Lewis JJ, Coit DG:, Sentinel lymph node biopsy in the management of patients with primary cutaneous melanoma: Review of a large single-institutional experience with an emphasis on recurrence. Ann Surg 2001; 233: 250-258. (Pubitemid 32106080)
70. Morton DL, Thompson JF, Cochran AJ, et al.: Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med 2006; 355: 1307-1317. (Pubitemid 44465459)
71. Balch CM, Gershenwald JE, Soong SJ, et al.: Melanoma staging and classification. In:, Balch CM, Houghton AN, Sober AJ, et al., editors. Cutaneous melanoma. St. Louis: Quality Medical Publishing, Inc.; 2009, 65-85.
72. Ross MI, Gershenwald JE:, How should we view the results of the multicenter selective lymphadenectomy trial-1 (MSLT-1) ? Ann Surg Oncol 2008; 15: 670-673.
73. Morton DL, Cochran AJ, Thompson JF, et al.: Sentinel node biopsy for early-stage melanoma: Accuracy and morbidity in MSLT-I, an international multicenter trial. Ann Surg 2005; 242: 302-311, discussion 311-303.
74. Gershenwald JE, Andtbacka RH, Prieto VG, et al.: Microscopic tumor burden in sentinel lymph nodes predicts synchronous nonsentinel lymph node involvement in patients with melanoma. J Clin Oncol 2008; 26: 4296-4303.
75. Govindarajan A, Ghazarian DM, McCready DR, Leong WL:, Histological features of melanoma sentinel lymph node metastases associated with status of the completion lymphadenectomy and rate of subsequent relapse. Ann Surg Oncol 2007; 14: 906-912. (Pubitemid 46175342)
76. Vuylsteke RJ, Borgstein PJ, van Leeuwen PA, et al.: Sentinel lymph node tumor load: An independent predictor of additional lymph node involvement and survival in melanoma. Ann Surg Oncol 2005; 12: 440-448. (Pubitemid 40884258)
77. Murali R, Desilva C, Thompson JF, Scolyer RA:, Non-Sentinel Node Risk Score (N-SNORE): A scoring system for accurately stratifying risk of non-sentinel node positivity in patients with cutaneous melanoma with positive sentinel lymph nodes. J Clin Oncol 2010; 28: 4441-4449.
78. ClinicalTrials.gov: Multicenter Selective Lymphadenectomy Trial II (MSLT-II). 2010.
79. EORTC: EORTC MINITUB Registration Study. 2010.
80. Thomas JM, Clark MA:, Selective lymphadenectomy in sentinel node-positive patients may increase the risk of local/in-transit recurrence in malignant melanoma. Eur J Surg Oncol 2004; 30: 686-691. (Pubitemid 39060740)
81. Estourgie SH, Nieweg OE, Kroon BB:, High incidence of in-transit metastases after sentinel node biopsy in patients with melanoma. Br J Surg 2004; 91: 1370-1371. (Pubitemid 39331464)
82. van Poll D, Thompson JF, Colman MH, et al.: A sentinel node biopsy does not increase the incidence of in-transit metastasis in patients with primary cutaneous melanoma. Ann Surg Oncol 2005; 12: 597-608. (Pubitemid 41126089)
83. Pawlik TM, Ross MI, Thompson JF, et al.: The risk of in-transit melanoma metastasis depends on tumor biology and not the surgical approach to regional lymph nodes. J Clin Oncol 2005; 23: 4588-4590.
84. Pawlik TM, Ross MI, Johnson MM, et al.: Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy. Ann Surg Oncol 2005; 12: 587-596. (Pubitemid 41126088)
85. Kang JC, Wanek LA, Essner R, et al.: Sentinel lymphadenectomy does not increase the incidence of in-transit metastases in primary melanoma. J Clin Oncol 2005; 23: 4764-4770. (Pubitemid 46224080)
86. Balch CM, Morton DL, Gershenwald JE, et al.: Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 2009; 60: 872-875.
87. Coit DG, Andtbacka R, Bichakjian CK, et al.: Melanoma. J Natl Compr Canc Netw 2009; 7: 250-275.
88. Cormier JN, Xing Y, Ding M, et al.: Population-based assessment of surgical treatment trends for patients with melanoma in the era of sentinel lymph node biopsy. J Clin Oncol 2005; 23: 6054-6062.
89. Erickson Foster J, Velasco JM, Hieken TJ:, Adverse outcomes associated with noncompliance with melanoma treatment guidelines. Ann Surg Oncol 2008; 15: 2395-2402.
90. Bilimoria KY, Balch CM, Wayne JD, et al.: Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol 2009; 27: 1857-1863.
91. National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology. Fort Washington, PA: NCCN, 2011. (.)
92. Bilimoria KY, Balch CM, Bentrem DJ, et al.: Complete lymph node dissection for sentinel node-positive melanoma: Assessment of practice patterns in the United States. Ann Surg Oncol 2008; 15: 1566-1576.